Bethesda, MD - The US FDA has approved mipomersen sodium (Kynamro, Genzyme, Cambridge MA), a once-weekly subcutaneous injection, as an adjunct to maximally tolerated lipid-lowering medications and ...
An FDA review raises a number of potentially significant safety concerns about the cholesterol-lowering drug mipomersen. The review appears ahead of a Thursday meeting of the Endocrinologic and ...
Amsterdam, the Netherlands - A novel antisense agent that reduces LDL production by inhibiting apolipoprotein B (apoB), mipomersen (Isis Pharmaceuticals/Genzyme), has shown some efficacy in a phase 2 ...
Genzyme's mipomersen, a promising new cholesterol drug, could offer new hope for patients who don't respond to existing lipid-lowering drugs such as statins. But there are also troubling questions ...
The FDA said today that it had granted approval to the novel cholesterol-lowering drug mipomersen sodium for use as an adjunct to diet and drug therapy in patients with homozygous hypercholesterolemia ...
CAMBRIDGE, Mass. & CARLSBAD, Calif., Feb 10, 2010 (BUSINESS WIRE) -- Genzyme Corp. (NASDAQ: GENZ) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) today announced that the phase 3 study of mipomersen in ...
On a rocky road toward hoped-for approvals, Sanofi's ($SNY) mipomersen has hit a serious rut with European regulators. A European Medicines Agency panel handed down a ...
Find out how to take Mipomersen Injection (drug) and its dose. Describes the best time to take the drug and precautions if any that should be followed.
Review the side-effects of Mipomersen Injection as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In ...
A new cholesterol lowering drug, mipomersen, reduces plasma low-density lipoprotein (LDL or bad cholesterol) by about 25% compared with placebo when added to existing therapies in patients who have ...
CAMBRIDGE, Mass. & CARLSBAD, Calif.--(BUSINESS WIRE)--Genzyme Corp., a subsidiary of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) announced today ...
In February, Isis announced its cholesterol-lowering antisense therapy, mipomersen, had met its endpoints in a phase 3 trial of 124 patients with heterozygous familial hypercholesterolemia (FH) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results